Sambucus nigra (Elderberry) supplements have demonstrated reduced duration of upper respiratory infection symptoms in several randomized double-blind placebo-controlled trials and meta-analyses (1,2,3). In vitro studies demonstrate that plant lectins, specifically mannose-binding lectins, possess antiviral activity against SARS-CoV family of coronaviruses (4,5). The lectin agglutinin I (SNA-If) isolated from the ripe elderberry fruit (Sambucus nigra) is the compound of interest. The proposed mechanism of action of Elderberry fruit on coronavirus activity, based on pre-clinical studies, suggests that lectin constituents inhibit the coronavirus spike protein during entry into human cells at the binding step thereby inhibiting the replication and viral attachment of human coronavirus. This immunological mechanism of the active compounds in Elderberry, and it's demonstrated reduction of symptom duration on influenza and other upper respiratory tract viruses, makes it a promising option in the treatment and prevention of COVID-19. However more rigorous research and human trials are needed (6).